Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose, Randomized, Two-Way Crossover, Bioequivalence of Lamotrigine 100 mg Tablet (Desitin Arzneimittel GmbH, Germany) and Lamictal 100 mg Tablet (GlaxoSmithKline GmbH & Co. KG, Germany) in Healthy, Male Volunteers, Fasting

NCT06199791 is registered in ClinicalTrials.gov with Desitin Arzneimittel GmbH as lead sponsor.

NCT NCT06199791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06199791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose, Randomized, Two-Way Crossover, Bioequivalence of Lamotrigine 100 mg Tablet (Desitin Arzneimittel GmbH, Germany) and Lamictal 100 mg Tablet (GlaxoSmithKline GmbH & Co. KG, Germany) in Healthy, Male Volunteers, Fasting
Lead sponsor
Desitin Arzneimittel GmbH
Phase
Phase 1
Overall status
Completed
Start date
April 3, 2023
Completion date
June 14, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fasting